Bosutinib effective in imatinib-resistant Ph+ CML-CP patients

March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p32
The article discusses research on the effectiveness of bosutinib in Philadelphia chromosome-positive (Ph+) chronic phase chronic melogenous leukemia (CML-CP) presented during the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia from December 8 to 11, 2007. According to the study by researchers from the University of Texas M.D. Anderson Cancer Center, CML-CP patients who were resistant to imatinib benefited from the orally bioavailable tyrosine kinase inhibitor.


Related Articles

  • Several SNPs identified that may predict imatinib response.  // Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p29 

    The article reports that several single nucleotide polymorphisms (SNPs) were identified by researchers at Princess Margaret Hospital in Toronto, Ontario and Samsung Medical Center in Seoul, South Korea. The SNPs may be used to determine the clinical response of imatinib in chronic myeloid...

  • Systematic review of dasatinib in chronic myeloid leukemia. Breccia, Massimo; Salaroli, Adriano; Molica, Matteo; Alimena, Giuliana // OncoTargets & Therapy;2013, Vol. 6, p257 

    Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy, for newly diagnosed chronic phase...

  • Biology: Three known unknowns. Bourzac, Katherine // Nature;5/29/2014, Vol. 509 Issue 7502, pS69 

    The article focuses on the role of drug imatinib for treatment of chronic myeloid leukaemia (CML) and the questions about drug resistant in cancer cells, cancer spread and role of normal tissue in cancer. Topics discussed include early clinical trails for the drug designed by clinical oncologist...

  • Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia. Okabe, Seiichi; Tauchi, Tetsuzo; Kimura, Shinya; Maekawa, Taira; Kitahara, Toshihiko; Tanaka, Yoko; Ohyashiki, Kazuma // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Resistance to imatinib (Gleevec®) in cancer cells is frequently because of acquired point mutations in the kinase domain of BCR-ABL. Ponatinib, also known as AP24534, is an oral multi-targeted tyrosine kinase inhibitor (TKI), and it has been investigated in a pivotal phase 2 clinical trial....

  • Imatinib.  // Reactions Weekly;7/22/2006, Issue 1111, p12 

    The article presents a case study of 73-year-old woman who developed joint effusions, while being treated with imatinib for Philadelphia chromosome-positive chronic myeloid leukaemia.

  • Cancer drug hope for eye diseases.  // Optometry Today;6/6/2014, Vol. 54 Issue 11, p7 

    The article discusses a study which found an alternative mechanism of imatinib drug used for treatment of leukemia that can help inhibit angiogenesis for prevention of blinding conditions such as diabetic retinopathy (DR) and age-related macular degeneration (AMD) as reported in "Medical Xpress."

  • Imatinib.  // Reactions Weekly;1/12/2008, Issue 1184, p22 

    The article describes the case of a 46-year-old man who developed liver injury while being treated with imatinib for FIP1L1-PDGFRA-associated chronic eosinophilic leukaemia with cardiac involvement. Imatinib was discontinued. Four weeks after imatinib discontinuation, the man's liver function...

  • Imatinib.  // Reactions Weekly;03/01/2013, Issue 1441, p19 

    The article presents a case study of a 58-year-old woman who developed hyperpigmentation of the hard palate during treatment with imatinib for chronic myeloid leukaemia (CML).

  • Imatinib.  // Reactions Weekly;12/9/2006, Issue 1131, p21 

    The article presents a case report of on myeodysplastic syndromes and acute leukemia developing after imatinib mesylane therapy, with reference to a study by C. Kovitz, G. Garcia-Manero et al., in the October 2006 issue of "Blood." The side effects of imatinib therapy are reported in several...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics